<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CYCLOPENTOLATE HYDROCHLORIDE <img border="0" src="../images/pr.gif"/></span><br/>(sye-kloe-pen'toe-late)<br/><span class="topboxtradename">Ak-Pentolate, </span><span class="topboxtradename">Cyclogyl, </span><span class="topboxtradename">Pentalair<br/></span><b>Classifications:</b> <span class="classification">eye preparation</span>; <span class="classification">cycloplegic</span>; <span class="classification">mydriatic</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.5%, 1%, 2% ophth solution</p>
<h1><a name="action">Actions</a></h1>
<p>Tertiary amine antimuscarinic compound with systemic side effects and CNS toxicity, similar to those of atropine. Acts by
         blocking response of iris sphincter muscle, and muscle of accommodation in the ciliary body to cholinergic stimulation.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>This results in dilation and paralysis of accommodation of the eyes. It binds to melanin in pupil; thus highly pigmented eyes
         may be less responsive to cycloplegic and mydriatic actions of the drug.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Induction of cycloplegia or mydriasis for ophthalmic diagnostic procedures.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Narrow angle glaucoma, excessively increased intraocular pressure; pregnancy (category C), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Elderly patients, brain damage (in children), Down's syndrome, spastic paralysis in children, blue-eyed individuals.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Cycloplegia or Mydriasis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Topical</span> 1 drop of 1% solution in eye 4050 min before procedure, followed by 1 drop in 5 min; may need 2% solution in
               patients with darkly pigmented eyes.<br/><span class="rdage">Child:</span> <span class="rdroute">Topical</span> 1 drop of 0.51% solution in eye 4050 min before procedure, followed by 1 drop in 5 min; may need 2% solution
               in patients with darkly pigmented eyes.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Topical</span><br/><ul>
<li>Clarify with physician which strength (1% or 2%) should be used.</li>
<li>Ask patient to remove soft contact lenses prior to installation of drops.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Flushing, fever. <span class="typehead">CNS:</span> Drowsiness dysarthria, disorientation, ataxia, hallucinations, hyperkinesis, psychosis, seizures.  <span class="typehead">CV:</span> Sinus tachycardia, hypotension. <span class="typehead">GI:</span> Dry mouth, abdominal distention in infants. <span class="typehead">Skin:</span> Rash, contact urticaria. <span class="typehead">Special Senses:</span> Burning, stinging, transient increases in intraocular pressure, irritation, punctate keratitis, blurred vision, hyperemia,
      synechiae, conjunctivitis, photophobia. <span class="typehead">Urogenital:</span> Urinary retention. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May interfere with the ocular antihypertensive effects of <b>carbachol,</b>
<b>pilocarpine,</b>
<b>physostigmine.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Peak:</span> 1560 min. <span class="typehead">Duration:</span> 24 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor cardiac status especially with preexisting heart disease.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not touch the dropper to any surface, including your skin or eyes.</li>
<li>Exercise caution when driving or engaging in other potentially hazardous activities as cyclopentolate ophthalmic may cause
            blurred vision. If you experience blurred vision, avoid these activities.
         </li>
<li>Protect your eyes when in bright light. Cyclopentolate ophthalmic may cause increased light sensitivity.</li>
<li>Do not wear soft contact lenses when the eye drops are being inserted.</li>
<li>Report immediately any of the following: difficulty breathing, swelling of your lips, tongue, face or hives; palpitations;
            and unusual behavior.
         </li>
<li>Do not breast feed while using this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>